Disitamab vedotin (RC48), a HER2-targeted antibody–drug conjugate containing monomethyl auristatin E (MMAE), is one of the novel molecules currently undergoing clinical evaluation for HER2-positive GC patients. This evidence concerns the gene ERBB2 and gastric cancer.